Verve Therapeutics, Inc. (VERV)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. (“Verve” or “the Company”) (NASDAQ: VERV). Investors who purchased Verve securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Verve has violated federal securities laws.
Investigation Details:
On April 2, 2024, Bloomberg published an article about Verve. According to the article, the Company “cited safety concerns for pausing enrollment in a study of its gene-editing treatment for people with high cholesterol, delivering a setback to the promising new field of medicine.” Following this news, Verve stock dropped over 40% in morning trading on the same day.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Verve securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | [email protected]